A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Clinical trial NCT02859441 · COMPLETED
Trial details
- NCT number
- NCT02859441
- Sponsor
- National Eye Institute (NEI)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-23
- Primary completion
- 2019-07-09
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.